Samsung Biologics Co Ltd (207940) — Cash Flow Reinvestment Rate
Samsung Biologics Co Ltd (207940) has a Cash Flow Reinvestment Rate of 0.35x as of September 2025, reinvesting ₩213.82 Billion (capex ₩113.81 Billion plus investments ₩-100.00 Billion) from operating cash flow of ₩619.30 Billion. Explore Samsung Biologics Co Ltd capital spending ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Samsung Biologics Co Ltd Cash Flow Reinvestment Rate (2017–2024)
Historical reinvestment intensity for Samsung Biologics Co Ltd across 7 annual periods. Also explore balance sheet size of Samsung Biologics Co Ltd for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Samsung Biologics Co Ltd (2017–2024)
Year-by-year capital reinvestment analysis for Samsung Biologics Co Ltd. For live market cap and broader valuation context, see Samsung Biologics Co Ltd (207940) market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 1.28x | ₩2.12 Trillion | ₩1.66 Trillion | ₩1.38 Trillion | ▼ -20.2% |
| 2023 | 1.60x | ₩2.67 Trillion | ₩1.67 Trillion | ₩1.11 Trillion | ▼ -22.5% |
| 2022 | 2.07x | ₩1.97 Trillion | ₩953.05 Billion | ₩956.84 Billion | ▲ +2.4% |
| 2021 | 2.02x | ₩918.63 Billion | ₩454.60 Billion | ₩406.25 Billion | ▼ -0.4% |
| 2020 | 2.03x | ₩409.83 Billion | ₩202.09 Billion | ₩139.66 Billion | ▼ -97.2% |
| 2019 | 72.36x | ₩734.74 Billion | ₩10.15 Billion | ₩192.84 Billion | ▲ +757.6% |
| 2017 | 8.44x | ₩1.26 Trillion | ₩149.82 Billion | ₩494.12 Billion | — |